ATE117685T1 - Chinoloncarbonsäure-derivate. - Google Patents

Chinoloncarbonsäure-derivate.

Info

Publication number
ATE117685T1
ATE117685T1 AT89108963T AT89108963T ATE117685T1 AT E117685 T1 ATE117685 T1 AT E117685T1 AT 89108963 T AT89108963 T AT 89108963T AT 89108963 T AT89108963 T AT 89108963T AT E117685 T1 ATE117685 T1 AT E117685T1
Authority
AT
Austria
Prior art keywords
general formula
compounds
quinoloonecarbonic
acid derivatives
hydrogen atom
Prior art date
Application number
AT89108963T
Other languages
English (en)
Inventor
Hiroyuki Nagano
Takeshi Yokota
Yasuyuki Katoh
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE117685T1 publication Critical patent/ATE117685T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT89108963T 1988-05-19 1989-05-18 Chinoloncarbonsäure-derivate. ATE117685T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12272288 1988-05-19
JP31041888 1988-12-08

Publications (1)

Publication Number Publication Date
ATE117685T1 true ATE117685T1 (de) 1995-02-15

Family

ID=26459793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89108963T ATE117685T1 (de) 1988-05-19 1989-05-18 Chinoloncarbonsäure-derivate.

Country Status (9)

Country Link
US (1) US5051509A (de)
EP (1) EP0342675B1 (de)
JP (1) JPH0395177A (de)
KR (1) KR940000368B1 (de)
AT (1) ATE117685T1 (de)
CA (1) CA1340285C (de)
DE (1) DE68920773T2 (de)
ES (1) ES2070142T3 (de)
HK (1) HK151295A (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
FR2656611B1 (fr) * 1990-01-04 1992-05-07 Hoechst France Nouvelles quinolones, leurs sels, utiles comme agents antimicrobiens, procede de preparation et leur application a titre de medicaments et compositions les renfermant.
FR2673426B1 (fr) * 1991-03-01 1993-07-16 Bouchara Sa Nouvelles quinolones, leur procede de preparation et les compositions en refermant.
FR2674854B1 (fr) * 1991-04-04 1995-03-03 Bouchara Nouvelles quinolones leur procede de preparation et les compositions pharmaceutiques en refermant.
FR2675144B1 (fr) * 1991-04-10 1995-06-16 Bouchara Sa Nouvelles quinolones difluorees - leur procede de preparation et les compositions pharmaceutiques en renfermant.
WO1993015070A1 (fr) * 1992-01-31 1993-08-05 Chugai Seiyaku Kabushiki Kaisha Cristal d'hydrate de derive d'acide quinolonecarboxylique
WO1993022308A1 (fr) * 1992-04-28 1993-11-11 Chugai Seiyaku Kabushiki Kaisha Procede pour produire un derive d'acide quinolonecarboxylique
FR2692577B1 (fr) * 1992-05-26 1996-02-02 Bouchara Sa Nouvelles quinolones fluorees, leur procede de preparation et les compositions pharmaceutiques en renfermant.
EP0726269B1 (de) * 1993-10-28 2001-09-05 Kaken Pharmaceutical Co., Ltd. Chinolincarbonsäurederivate und ihre salze
US5686095A (en) * 1995-10-23 1997-11-11 Price, Jr.; Francis W. Method of treating canker sores
US6387928B1 (en) * 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
RU2193558C2 (ru) * 1997-09-15 2002-11-27 Дзе Проктер Энд Гэмбл Компани Производные хинолона и фармацевтическая композиция на их основе
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6608078B2 (en) 2000-05-08 2003-08-19 Wockhardt Limited Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
US7098219B2 (en) 2000-08-01 2006-08-29 Wockhart Limited Inhibitors of cellular efflux pumps of microbes
US6964966B2 (en) 2001-04-25 2005-11-15 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US6878713B2 (en) 2001-04-25 2005-04-12 Wockhardt Limited Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
US7423153B2 (en) * 2002-05-10 2008-09-09 Teva Pharmaceutical Industries Ltd. Crystalline forms of gatifloxacin
WO2003099815A1 (en) 2002-05-28 2003-12-04 Wockhardt Limited Crystalline fluoroquinolone arginine salt form
US6900224B2 (en) * 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1660495B1 (de) 2003-09-04 2007-07-11 Wockhardt Limited Benzochinolizin-2-carbonsäureargininsalz- tetrahydrat
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US7456279B2 (en) * 2006-03-28 2008-11-25 The Procter & Gamble Company Coupling process for preparing quinolone intermediates
BRPI0709209A2 (pt) * 2006-03-28 2011-06-28 Procter & Gamble processo de redução de hidreto para preparo de intermediários de quinolona
DK2001862T3 (da) 2006-03-28 2011-08-08 Warner Chilcott Co Llc Malatsalte og polymorfe af (3S,5S)-7-[3-amino-5-methyl-piperidinyl]-1-cyklopropyl-1,4-dihydro-8-methoxy-4-oxo-3-quinolincarboxylsyre
MX2008014024A (es) 2006-05-04 2008-11-14 Boehringer Ingelheim Int Formas poliformas.
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (de) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Zusammensetzungen von DPP-IV-Inhibitoren
TWI362386B (en) 2007-03-30 2012-04-21 Daiichi Sankyo Co Ltd A production method for the qunolon-carboxylic acid derivative
CN101450938B (zh) * 2007-12-04 2012-11-14 中国医学科学院医药生物技术研究所 7-(4-肟基-3-氨基-3-烷基-1-哌啶基)喹啉羧酸衍生物及其制备方法
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP3646859A1 (de) 2009-11-27 2020-05-06 Boehringer Ingelheim International GmbH Behandlung von genotypisierten diabetes-patienten mit dpp-iv-hemmern wie etwa linagliptin
AU2011249722B2 (en) 2010-05-05 2015-09-17 Boehringer Ingelheim International Gmbh Combination therapy
CN106975074A (zh) 2010-06-24 2017-07-25 勃林格殷格翰国际有限公司 糖尿病治疗
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
PH12014500137A1 (en) 2011-07-15 2017-08-18 Boehringer Ingelheim Int Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
WO2013056165A1 (en) 2011-10-12 2013-04-18 Yoseph Yaacobi Contact lens cleaning systems
CN102558145B (zh) * 2011-12-14 2014-04-16 中国药科大学 巴洛沙星的制备方法
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (de) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medizinische verwendung eines dpp-4-inhibitors
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777175A (en) * 1982-09-09 1988-10-11 Warner-Lambert Company Antibacterial agents
JPS62469A (ja) * 1985-06-27 1987-01-06 Dainippon Pharmaceut Co Ltd 新規キノロン誘導体、そのエステルおよびその塩
JPH089597B2 (ja) * 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
JPS63198664A (ja) * 1986-03-31 1988-08-17 Sankyo Co Ltd キノロンカルボン酸誘導体
CN1019114B (zh) * 1986-03-31 1992-11-18 三共株式会社 喹啉-3-羟酸衍生物的制备方法
US4771055A (en) * 1986-07-28 1988-09-13 Warner-Lambert Company 7-[[3-(aminomethyl)-3-alkyl]-1-pyrrolidinyl]-quinoline-carboxylic acids
US4851418A (en) * 1987-08-21 1989-07-25 Warner-Lambert Company Naphthyridine antibacterial agents containing an α-amino acid in the side chain of the 7-substituent

Also Published As

Publication number Publication date
JPH0395177A (ja) 1991-04-19
EP0342675B1 (de) 1995-01-25
KR940000368B1 (ko) 1994-01-19
US5051509A (en) 1991-09-24
EP0342675A3 (en) 1990-12-27
DE68920773D1 (de) 1995-03-09
JPH0555506B2 (de) 1993-08-17
ES2070142T3 (es) 1995-06-01
HK151295A (en) 1995-09-29
KR890017243A (ko) 1989-12-15
EP0342675A2 (de) 1989-11-23
CA1340285C (en) 1998-12-22
DE68920773T2 (de) 1995-05-18

Similar Documents

Publication Publication Date Title
ATE117685T1 (de) Chinoloncarbonsäure-derivate.
ZA888186B (en) Quinolinecarboxylic acid derivatives
NZ248099A (en) Use of spiro-oxathiolane quinuclidine derivatives for treating sjoegren syndrome
AU591640B2 (en) Quinolonecarboxylic acid derivatives
ATE251157T1 (de) Bicyclische aminderivate
DK0784055T3 (da) Pyrimidinylpyrazolderivater
KR0141683B1 (en) Naphthoic acid derivative
ES2065994T3 (es) Beta-dicetonas substituidas.
DK0806413T3 (da) 2-substituerede viatmin D3-derivater
CA2221946A1 (en) Production process of cyclic compound
ATE86629T1 (de) 4-piperidincarboxamid-derivate.
ATE189813T1 (de) Prostaglandin-i-analoga
ES2090155T3 (es) Derivados de ciclopropacromen.

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time